Specialty products segment key to Sun Pharma's growth prospects

The Sun Pharma stock gained 1.38 per cent on Thursday, even as the firm posted a weaker-than-expected performance for the March quarter. This was on account of the specialty products segment, which put up a better-than-expected show. This segment is vital to Sun Pharma’s growth prospects. The firm refrained from providing growth guidance for FY21, considering the prevalent uncertainty. Though its US subsidiary Taro surpassed expectations in the quarter, pricing pressure in the overall portfolio is keeping analysts cautious. Further, with some softening in revenue expected in .....

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel
Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.